Latest Imprimis Pharmaceuticals Inc. Stories
Patent-pending ophthalmic formulation fourth quarter 2014 revenues increased by over 101% compared to third quarter 2014 revenues for the same products SAN DIEGO, March 12, 2015 /PRNewswire/
SAN DIEGO, March 4, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Investigator reports that Imprimis' combination compounded Tri-Moxi and Pred-Moxi formulations produced equivalent patient outcomes compared to traditional standard of care individual eye drops, while
John Saharek Appointed to Chief Commercial Officer and Andrew R. Boll to Chief Financial Officer SAN DIEGO, Feb. 2, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Dropless Therapy(TM) injectable and planned LessDrops(TM) topical compounded formulations offer the same patent-pending technology and the promise of significantly reducing or completely eliminating
Proprietary topical compounded formulations offer the promise of significantly reducing the number of patient eye drop administrations as well as the high cost of eye drops typically required for traditional
Highly-acclaimed leader in ophthalmology adds clinical expertise to Board SAN DIEGO, Jan. 5, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Dropless Cataract Therapy now available in California, Nevada, Oregon, and Hawaii SAN DIEGO, Dec. 3, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Agreement to acquire Park Compounding marks an important milestone and a significant step forward to achieving nationwide distribution capability for Imprimis' patent-pending ophthalmic and urologic
Patent-pending ophthalmic formulation revenues increased over 190% compared to the second quarter 2014 SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.